Celyad: William Wijns To Resign As Charirman, To Chair CHART-1 Committee

(RTTNews) - Celyad (CYAD), a developer of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology, announced Monday that William Wijns has been appointed as Chairman of the CHART-1 Steering Committee.

In his role, he will oversee the scientific committee in charge of the data analysis and data dissemination plan for the trial. In order to avoid any potential conflict of interest Wijns will resign from the Board of Celyad.

Congestive Heart failure Cardiopoietic Regenerative Therapy or CHART-1 is a patient prospective, controlled multi-centre, randomized, double-blinded Phase III clinical trial comparing treatment with C-Cure to a sham treatment. The trial has recruited 240 patients with chronic advanced symptomatic heart failure in Europe and Israel.

Wijns has served as a member of the Board of Directors of Celyad since 2007 and is also a co-founder of the Company.

From April 2016, he will step down from the Board to chair the independent experts' committee. Wijns does not have any remaining interest in the company.